Monday, January 7, 2019
CytoSorbents sees FY18 revenue at least $22.3M, consensus $22.71M
The company expects to announce record results including: Full year 2018 total revenue of at least $22.3M, with additional 2018 grant revenue expected upon finalization of invoicing; Full-year product sales in 2018 of approximately $20.2M, an increase of approximately 51% compared to $13.4M in 2017, and record Q4 2018 product sales of approximately $5.4M; 2018 blended gross product margins in excess of 72%, mixing higher margin direct sales and lower margin distributor and partner sales; More than 56,000 CytoSorb cumulative treatments delivered, up from 35,000 treatments a year ago; End-of-year cash position of approximately $22.3M (12/31/18).
https://thefly.com/landingPageNews.php?id=2844703
Eli Lilly says ‘very much’ wants to continue Loxo’s partnership with Bayer
https://thefly.com/landingPageNews.php?id=2844705
STAAR Surgical sees FY18 revenue about $124M, consensus $123.27M
“Global demand for our ICL product lines continued to expand during the fourth quarter, and all signs currently point to this momentum continuing into 2019,” said Caren Mason, President and CEO. “China led the way with ICL unit growth of approximately 99% in the fourth quarter, sequentially consistent with the growth we reported for the third quarter of 2018. As we planned, STAAR Surgical’s business in the U.S. also returned to growth. We began the staged rollout of the Toric ICL in the U.S. to certified surgeons in late October leading to approximately 16% growth for the ICL in the U.S., compared to the prior year period, in the world’s second largest refractive surgery market.”
https://thefly.com/landingPageNews.php?id=2844711
Eli Lilly says will continue to look in oncology for deals
Says will also look in other therapeutic areas for M&A.
https://thefly.com/landingPageNews.php?id=2844717
Sunday, January 6, 2019
Biocartis Announces Achieving its 2018 Key Business Objectives
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces to have achieved its 2018 key business objectives.
Biocartis’ key business objectives for 2018 were focused on three performance indicators: installed base expansion of its Idylla™ molecular diagnostics platform, cartridge volume growth and the Company’s year-end cash position.
Based on non-audited numbers, Biocartis now reports meeting or exceeding these business objectives:
- Installed base – Biocartis realized 326 new instrument placements in 2018, exceeding the latest guidance of 300 new instrument placements. Biocartis’ installed base as per 31 December 2018 consequently grew to around 970 Idylla™ instruments.
- Cartridge volume – In 2018, Biocartis realized a commercial volume of approx. 133k cartridges, in line with the latest guidance of 130k – 135k cartridges.Biocartis’ 2018 commercial cartridge volume represents a year-over-year increase of approx. 87%.
- Cash position – As per 31 December 2018, Biocartis’ cash position amounted to EUR 64m (non-audited number) versus the latest guidance of around EUR 55m. No drawdowns on the Company’s multiple purpose credit facility of EUR 27.5m were made as per year-end 2018.
Other key achievements in 2018 that are expected to support further business growth, include amongst others:
- US – Successful initial roll-out of the Idylla™ platform in the US during the first full year of commercialization in that market, attracting reference customers such as Memorial Sloan Kettering Cancer Center (New York) and Dartmouth -Hitchcock Medical Center (New Hampshire);
- China – Announcement of joint venture with Wondfo for commercialization of the Idylla™ platform in China;
- Japan – Selection of commercialization partner for Japan, resulting into signing of a distribution agreement with Nichirei Bioscience as announced on 7 January 2019;
- Menu of molecular diagnostic tests – Continued menu expansion with the launch of the Idylla™ MSI Assay (RUO1);
- Test content partnerships – Expansion of the collaboration with Genomic Health Inc. into the field of urology with the planned development of an Idylla™ Oncotype DX GPS test and potentially additional cancer tests. Progression of the Idylla™ Oncotype Breast Recurrence Score® test towards launch; and
- Partnerships with pharmaceutical partners – New agreement with AstraZeneca aimed at demonstrating that Idylla™ can overcome the long turnaround time forlung cancer biomarker results.
Herman Verrelst, Chief Executive Officer of Biocartis, comments: “I am pleased we can announce today that we have achieved our key 2018 objectives. The growth in instrument installed base and the year-over-year ramp-up of cartridge volume are clear indicators of the commercial growth curve that we are on. We have significantly strengthened our global commercial footprint in 2018. With the recent signing of the commercialization agreement for the Japanese market we now have a commercial network in all major markets worldwide. As we furthermore continue to grow the assay menu on the Idylla™ platform and expand our partner network, Biocartis is in a solid position to execute upon its mission to offer rapid and easy molecular diagnostic solutions aimed at enabling faster and more accurate treatment decisions for oncology patients across the globe.”
Biocartis will publish its 2018 full year results and 2019 guidance on 28 February 2019. Next to a live webcast that day, Biocartis will also host a Capital Markets Day tailored for institutional investors, research analysts and sector journalists to provide amongst others an update on the Company’s test menu strategy. On 10 January 2019,
Biocartis will present at the 37th Annual J.P. Morgan Healthcare conference in San Francisco, California (US) at 10:30 PST /19:30 CET.
Anthem (ANTM) Upgraded at Evercore
Evercore ISI upgraded shares of Anthem (NYSE:ANTM) from an in-line rating to an outperform rating in a report issued on Thursday morning, MarketBeat reports. The firm currently has $255.02 target price on the stock.
Subscribe to:
Posts (Atom)